Enabling Technologies to Accelerate Development of Oral Biodevices (R01, R21 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

Companion FOA: PAR-20-232 - Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)


  •  R01 Due Dates: Feb. 5, Jun 5, Oct. 5
  • R21 Due Dates: Feb. 16, Jun. 16, Oct. 16
  • AIDS Due Dates: Jan. 7, May 7, Sep. 7

PAR-20-233 Expiration Date May 08, 2023




Engineering and Physical Sciences
Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 5, 2023